Aesica Appoints New Site Manufacturing Manager at Cramlington Facility
News Nov 26, 2013
Aesica has announced the appointment of Catherine Dick to the new role of site manufacturing manager at Cramlington. She will take responsibility for ensuring that all manufacturing is performed as planned from product introduction through all aspects of the manufacturing process.
A key function for Catherine is to ensure that every activity scheduled is kept on track for products during the remainder of 2013.
This includes the completion of manufacturing work on approximately 4 new products, at multiple stages of development, due to be brought on to the Cramlington site in 2014, each of which will be manufactured for a key strategic partner of Aesica.
Catherine brings strong experience and knowledge of operations at Cramlington to the task in hand, having joined Aesica back in 2007 as the site’s Quality Manager.
In 2010, she was promoted to Head of Quality for UK API (Active Pharmaceutical Ingredients), responsible for the quality and regulatory compliance of all products manufactured across both the Cramlington and the Queenborough API manufacturing sites.
Recently, she headed up the latest Queenborough API MHRA site inspection, carried out voluntarily by the company every three years.
Mark Dawson will now take the helm as Head of Quality at the Cramlington facility. With over 25 years’ experience in the API industry, Mark has held various roles at the site within the Quality Control, EH&S and Warehousing departments.
In his most recent role, he spent thirteen years as part of the production management team responsible for the day-to-day running of the process plants on the Cramlington site.
The company is also set to recruit three new chemists, a site engineering manager and an analytical technology officer.
Catherine had previously worked as QA Manager and as a project manager for a small biotechnology company prior to joining Aesica.
She holds an MSC research fellowship in mechanisms of iron uptake in plants, microbes and mammalian cells, a PhD in BioChemistry from Newcastle University and a degree in BioChemistry and Genetics from Durham.
Steve Barker, Operations Director, API Business Unit at Aesica remarked: “Catherine possesses strong expertise and a solid knowledge of implementing work on multiple, quality APIs. The acumen she brings to the role coupled with the collective quality measures we are taking will ensure the company operates to the most rigorous, cost effective and timely manufacturing processes.”
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018